The importance of antiandrogen in prostate cancer treatment

Camille Lanz¹, Mostefa Bennamoun², Petr Macek¹, Xavier Cathelineau¹, Rafael Sanchez-Salas¹

¹Department of Urology, ²Department of Oncology, Mutualist Montsouris Institute, 42 Boulevard Jourdan, Paris, France

Correspondence to: Rafael Sanchez-Salas, MD. Department of Urology, Mutualist Montsouris Institute, 42 Boulevard Jourdan, 75014 Paris, France.
Email: raersas@gmail.com; rafael.sanchez-salas@imm.fr.

Provenance: This is an article commissioned by the Guest Section Editor Weijun Jiang (Nanjing Normal University, Department of Reproductive and Genetics, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China).


Submitted Aug 09, 2019. Accepted for publication Sep 05, 2019.
doi: 10.21037/atm.2019.09.53

© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2019 | http://dx.doi.org/10.21037/atm.2019.09.53

The importance of antiandrogen in prostate cancer treatment

Since 2011, Docetaxel is no longer the exclusive treatment for castration-resistant prostate cancer (CRPC), with the emergence of a new generation of hormonal treatments (1-4). Although the first antiandrogens generation has shown clinical benefit, their low affinity for the androgen receptor (AR) allows for the 5% to 10% of free dihydrotestosterone in the prostate to activate the AR (1). Antiandrogens, such as enzalutamide and apalutamide, have nowadays a major role in CRPC treatment. Indeed, enzalutamide has shown an overall survival (OS) improvement in metastatic castration-resistant prostate cancer (mCRPC), before and after chemotherapy (PREVAIL and AFFIRM trials respectively) (5,6), and a metastatic-free survival (MFS) improvement in non-metastatic castration-resistant prostate cancer (M0CRPC) (PROSPER trial) (7). Subsequently, SPARTAN (Selective Prostate Androgen Receptor Targeting with ARN-509), a randomized placebo-controlled Phase 3 trial, evaluated the benefits of apalutamide on MFS in men with M0CRPC, with all treated by androgen deprivation therapy (ADT), and at a high risk of developing metastases, as defined by a doubling of the prostate-specific antigen time (PSA-DT) of 10 months or less. Its results reported on an improvement in MFS with apalutamide in M0CRPC (8).

Place of AR in prostate cancer treatment

Huggins and Hodges established the sensitivity to androgen in prostate cancer by observing that a low circulating androgen level could reduce the advanced prostate cancer symptoms (9). The discovery of ARs in the late 1960s led to the understanding that their activations could induce the translocation from the cytoplasm to the nucleus, and thus the expression of proliferation genes. The ADT, by surgical or medical castration, delays this proliferation for a limited period, until the PSA level rises, suggesting a disease progression into a castration-resistance (1). Whereas the disease becomes refractory to the gonadotropin-releasing hormone (GnRH) axis inhibition, the observed response to hormonal manipulations with other agents, such as ketoconazole or diethylstilbestrol, suggests the existence of another pathway (1). The significant levels of androgen in the prostate cancer cells, even though the circulating testosterone level remains at a 95% decrease, as observed by Labrie in the 1980s (10), is probably provided by the transformation of dehydroepiandrosterone from the adrenal origin into testosterone in the peripheral tissues intracrinology function. This emphasizes that the androgen signal could represent a major role in the disease control. According to Crawford, an optimized androgenic blockage by combining ADT and antiandrogen at the initiation of ADT, or after the disease progression, could improve the treatment effectiveness (11). The latter has led to the emergence of treatments using competitive ligands for AR.

Place of antiandrogen in prostate cancer

The AR inhibitors compete with the endogenous androgens for the AR ligand-biding domain. They block the androgen signal by inhibiting the nuclear translocation. The first
Steroidal antiandrogens have given way to safer and more specific nonsteroidal antiandrogens (1). The first generation that was composed by flutamide and nilutamide when combined to ADT, improves the OS between 3 to 8 months, and extends the progression-free survival (PFS) of metastatic castration-sensitive prostate cancer (m1CSPC) (16.5 months with flutamide vs. 13.9 months with placebo, P=0.039; and 20.8 months with nilutamide and 14.9 months with placebo, P=0.005) (1,11,12). The second generation, bicalutamide, had a relatively modest clinical benefit since when alone, no difference with the standard of care has been underlined on the survival in men with locally advanced and metastatic disease (1,13,14). According to the Early Prostate Cancer (EPC) trial program that evaluated bicalutamide in a localized or locally advanced disease, bicalutamide improved the PFS of patients with a locally advanced disease, especially for those who had undergone radiotherapy (P=0.0031) (1,13). The new antiandrogen generation (enzalutamide, apalutamide, darolutamide), with a higher affinity to the AR, optimizes the androgen blockade effect. Enzalutamide was the first approved antiandrogen by the FDA in 2012. It has a five to eightfold higher affinity for the AR than bicalutamide. Its clinical efficiency was verified in mCRPC (81% and 29% reduction in the risk of radiographic progression and death, respectively, with enzalutamide and ADT), and in M0CRPC (71% lower risk of metastasis or death than placebo) (6,7,15-17). Darolutamide is currently evaluated in m1CSPC when added to ADT and docetaxel in ARASENS (NCT02799602), in M0CRPC in ARAMIS (NCT02200614), and in mCRPC in ARASENS (NCT02799602).

### Apalutamide

Apalutamide is an oral third-generation nonsteroidal AR inhibitor that was discovered in 2007 and approved by the FDA in 2018. It is closely related to enzalutamide with a similar mechanism of action. Its affinity to AR is five to tenfold higher than bicalutamide. Unlike enzalutamide, apalutamide does not cross the blood-brain barrier and has a greater antitumor activity at a lower dose.

Different studies have reported that apalutamide could reduce the PSA level from 46% to 89% in mCRPC and in M0CRPC (18,19). SPARTAN observed an MFS improvement with apalutamide when compared to a placebo (40.5 and 16.2 months, respectively, hazard ratio (HR) 0.28; P<0.001) in M0CRPC, and with a significantly longer time to the symptomatic progression with apalutamide (HR, 0.45) (8). Since then, apalutamide has been recommended for the treatment of patients with M0CRPC (8). It has generated 5 trials: at an earlier stage as in low risk prostate cancer (Active Surveillance with or without Apalutamide Treatment in Low Risk Prostate Cancer, NCT03088124); localized high risk disease (ATLAS, NCT02531516); biochemical recurrence (EMBARK, NCT02319837), and m1CSPC (TTTAN, NCT02489318) (20); as well as at a more advanced stage as mCRPC (ACIS, NCT02257736).

### Place of apalutamide in international guidelines and the standard of care in patients with m1CSPC in 2019

Among the EAU, NCCN, AUA, and AFU2019 guidelines, the place of apalutamide mainly concerns patients with M0CRPC, who are at a high risk of metastases (as assessed by a PSA-DT $\leq$ 10 months). They all recommend combining a new antiandrogen, with either apalutamide or enzalutamide, with ADT.

In the case of m1CSPC, they all recommend introducing an ADT to palliate the symptoms and reduce the risk of metastasis complications. While the guidelines are unclear for a low risk and volume because of a lack of evidence, they all advise combining ADT to an adjuvant therapy, such as docetaxel, for the high-volume disease, and abiraterone with prednisone for the high-risk ones. According to CHAARTED (which evaluated docetaxel when combined with ADT versus ADT alone in m1CSPC), a high metastases volume represents at least 4 bone metastases, including 1 outside the axial skeleton, or visceral metastasis (21). According to LATITUDE (which evaluated abiraterone plus prednisone when combined to ADT versus ADT alone in m1CSPC), a high-risk disease included at least 2 high-risk features ($\geq$ 3 bone metastasis, visceral metastasis, and a grade $\geq$4 ISUP score) (22).

### Apalutamide for metastatic, castration-sensitive prostate cancer—TITAN

The Targeted Investigational Treatment Analysis of Novel Anti-androgen trial (TTTAN) that was published in May 2019 in the New England Journal of Medicine was a double-blind Phase 3 randomized trial designed by Chi et al. They aimed to assess the benefits of apalutamide (240 mg per day) when compared to a placebo, with both of them in a combination with ADT, on OS and radiographic
progression-free survival (RFPS) in 1,052 patients with m1CSPC, while at the same time, maintaining a reasonable health-related quality of life. After a median follow-up of 22.4 months, TITAN reported a significant improvement in RFPS and OS at 24 months in the apalutamide group [68.2% in the apalutamide group vs. 47.5% in the placebo group, HR 0.48, 95% confidence interval (CI), 0.39 to 0.60; P<0.001; and 82.4% in the apalutamide group vs. 73.5% in the placebo group, HR 0.67; 95% CI, 0.51 to 0.89; P=0.005, respectively], with a quality of life preservation.

**Radiographic progression-free survival (RPFS)**

TITAN was the first Phase 3 trial comparing the benefits of apalutamide upon m1CSPC, whatever the metastasis volume. As well as the equivalent clinical trials which evaluated ADT when associated with either enzalutamide or a placebo (ARCHES - NCT02446405 - results presented at ASCO-GU 2019), or ADT when associated with either enzalutamide or an older generation nonsteroidal antiandrogen (ENZAMET - NCT02677896 - results presented at ASCO-GU 2019) (Table 1), TITAN reported a real RPFS improvement at 24 months (68.2% in the apalutamide group and 47.5% in the placebo group; HR 0.48; 0.39 to 0.60; P<0.001), leading to a 52% lower risk of radiographic progression or death in the apalutamide group. This result was really close to the 53% lower risk of radiographic progression or death in the abiraterone group (HR, 0.47; 0.39 to 0.55; P<0.001), as reported by LATITUDE on m1CSPC (Table 1) (22). This supported the hypothesis that androgen signal inhibition could significantly delay the disease progression and should probably have a place at an earlier stage of the disease.

Furthermore, this benefit of apalutamide remains favorable in the different subgroups analyzed (previous docetaxel, high or low disease volume). In fact, ARCHES and ENZAMET reported on the same conclusion with enzalutamide. However, probably because of a high proportion of the 40% patients who received a prior therapy with docetaxel in ENZAMET, the clinical PFSs were lower, but they were significant in the different subgroups. It is not clear whether this needs a longer follow-up, or if it is the consequence of the prior treatment.

**Overall survival (OS) (Figure 1)**

The major strength of TITAN was to identify a significant favorable benefit on OS since 82.4% of the patients were alive at 24 months in the apalutamide group and only 73.5% in the placebo group (HR for death, 0.67; 0.51 to 0.89; P=0.005). Thus, apalutamide provides a 33% lower risk of death. This reflects, in particular, on the advantages of apalutamide, since those patients with a high volume m1CSPC did not consistently receive the gold standard treatment, docetaxel or abiraterone associated with ADT, but they still presented a longer OS (HR 0.68; 0.50–0.92) (20). This is consistent with the significant 38% lower relative risk of death in patients from the abiraterone group as reported in LATITUDE, despite its population heterogeneity (Table 1, Figure 1), and it underlined that by improving the androgen signal inhibition, it could improve patients with m1CSPC survival (22). Nowadays, the results on OS for enzalutamide are insufficient. While ENZAMET had also observed an improvement in OS when treated with enzalutamide at 3 years (Table 1, Figure 1), ARCHES' OS data are so far immature, but it tended to be favorable to enzalutamide. As well as being significant, the OS benefit in TITAN occurs earlier with apalutamide, after 2 years of treatment.

In addition, the apalutamide benefit remains significant, whatever the disease volume, while the effect of enzalutamide in the stratified groups of ENZAMET appeared to be less consistent and not significant, notably in the high volume disease. Finally, TITAN's OS results for patients who received a prior therapy with docetaxel tended to be favorable, but they were not significant (HR 1.27), as ENZAMET had described it for enzalutamide.

According to TITAN, apalutamide could improve patients with an m1CSPC survival, whatever the disease volume. This led the investigators to unblind the trial, which was really unclear with enzalutamide. However, the best treatment for patients who have already received docetaxel remains unclear.

**Adverse event—quality of life**

Just as SPARTAN had on a low discontinuation level due to apalutamide adverse events in mCRPC without a significant difference (10.6% in the apalutamide group and 7.0% in the placebo group), TITAN observed a lower rate of 8% of interrupted treatments by apalutamide because of adverse events, with 5.3% in the placebo group. Furthermore, TITAN observed a lower rate of grade 3 or 4 events and a lower difference between groups than did SPARTAN (42.2% and 45.1% in the apalutamide groups, and 40.8% and 34.2% in the placebo groups, respectively), as well
| Table 1 Characteristics and results of the phase 3 randomized trials upon mICSPC |
|--------------------------------------|-------------------------------------------------|-----------------|--------------------------------------|-------------------------------------------------|
| TITAN (apalutamide) (20)             | ARCHES (enzalutamide) (report from ASCO GU 2019) | ENZAMET (enzalutamide) (23) | LATITUDE (abiraterone) (22) |
| Apalutamide (240 mg/day) + ADT vs. placebo + ADT | Enzalutamide (160 mg/day) + ADT vs. placebo + ADT | Enzalutamide (160 mg/day) + ADT vs. (bicalutamide/flutamide/nilitumide) + ADT | AA (1,000 mg/day) + prednisone (5 mg) + ADT vs. dual placebo + ADT |
| Apalutamide: 525 patients            | Enzalutamide: 574 patients                      | Enzalutamide: 563 patients | Abiraterone + prednisone: 597 patients |
| Placebo: 527 patients                | Placebo: 576 patients                           | Bicalutamide/flutamide/nilitumide: 562 patients | Placebo: 602 patients |
| Median age: 68 years old             | Median age: 70 years old                        | Median age: 68 years old | – |
| ECOG 0–1                             | ECOG 0–1                                        | ECOG 0–2          | ECOG 0–2 |
| 67% Gleason score >7                 | 66% Gleason score >8 at baseline                | 58% Gleason score >8 at baseline | – |
| Previous treatment                   | Previous treatment                              | Previous treatment | Excluded if |
| 16.4%: prostatectomy or radiotherapy | 17.8%: docetaxel                                | 42%: prostatectomy | previous chemotherapy |
| 10.7%: docetaxel                     | 91%: ADT                                        | 45%: docetaxel    | radiation therapy |
| 37.7% antiandrogen                   |                                                |                  | surgery for metastatic prostate cancer |
| 62.7% high disease volume            | 63% high disease volume                        | 52% high disease volume | – |
| 37.3% low disease volume             | 37% low disease volume                         | 47% low disease volume | – |
| Median follow-up: 22.7 months        | Median follow-up: 14.4 months                  | Median follow-up: 34 months | Median follow-up: 30.4 months |
| Results: RPFS at 24 months           | Results: RPFS at 12 months                     | Results: clinical progression-free survival at 3 years | Results: RPFS |
| 68.2% vs. 47.5%                      | 84% vs. 64%                                    | 68% vs. 41%       | 33 vs. 14.8 months |
| HR 0.48; 0.39–0.60; P<0.001          | HR 0.39; 0.30–0.50; P<0.0001                    | HR 0.40; 0.33 to 0.49; P<0.001 | HR 0.47; 0.39–0.55; P<0.001 |
| 52% lower risk of radiographic progression or death | | 53% lower risk of radiographic progression or death | |
| OS at 24 months                      | OS: IMMATURE                                    | OS at 3 years     | OS at 3 years |
| 82.4% vs. 73.5%                      | 80% vs. 72%                                    | 66% vs. 49%       | 66% vs. 49% |
| HR 0.67, P=0.005                     | HR 0.67; 0.52–0.86; P=0.002                     | HR 0.62; 0.51–0.76; P<0.001 | Grade 3 or 4 adverse events |
| Grade 3 or 4 adverse events          |                                                | Grade 3 or 4 adverse events | |
| 42.2% vs. 40.8%                      |                                                | 63% vs. 48%       | |

ADT, androgen deprivation therapy; RFPS, radiographic progression-free survival; OS: overall survival; HR, hazard ratio; AA, abiraterone acetate.
as a lower serious adverse events rate (19.8% and 24.8%, respectively), and an identical death rate due to apalutamide (8,20). Thus, both TITAN and SPARTAN have suggested that apalutamide provides a good quality of life, especially in TITAN, in which the best tolerance to apalutamide was probably due to patients with an early-stage disease and an ECOG score of between 0 and 1. That raises the matter of vulnerable patient treatments options.

The health-related quality of life in TITAN was evaluated thanks to changes from the baseline in the The Functional Assessment of Cancer Therapy–Prostate Questionnaire (FACT-P), and this seemed to be preserved in both groups. According to LATITUDE, a better AR signal inhibition also improved the quality of life. Indeed, despite 12% discontinuation of abiraterone due to adverse events (22), the median time to deterioration in functional status, assessed by the same tool, was longer in the abiraterone group than in the placebo group (12.9 and 8.3 months respectively, HR 0.85; P=0.032). The addition of abiraterone and prednisone would therefore appear to delay the progression of pain, fatigue and also offer a good quality of life (24), despite a higher treatment interruption rate than apalutamide. A trial comparing apalutamide and abiraterone could evaluate which one provides a better quality of life.

Using the same FACT-P tool for enzalutamide, ARCHES’ data, so far immature, tended toward a preserved quality of life but with no difference between the groups over the length of the study. However, ENZAMET identified 12% of discontinuation for other reasons than disease progression, and more 1 to 3 adverse events, including fatigue and the risk of seizure, and even more so, when the patients had already been treated by docetaxel. It is nevertheless difficult to identify if the toxic effects corresponded to enzalutamide alone, or to docetaxel (24).
According to this result, apalutamide is the only antiandrogen that underlined a significant improvement on OS and RPFS in m1CSPC, while keeping a good quality of life.

**Conclusions**

ADT alone is insufficient for the management of metastatic prostate cancer since most patients with m1CSPC will progress to the castration-resistant disease within 1 year (25). TITAN confirms LATITUDE’s hypothesis, suggesting that a stronger AR signaling inhibition is required to improve patients with m1CSPC outcomes. Apalutamide is currently the only antiandrogen that has shown a sooner real benefit in OS after 2 years of treatment, with an acceptable tolerance (20). This could change the management of m1CSPC and help to choose between the different antiandrogens. This benefit is observed at different stages of the disease (resistance to castration, regardless of the disease volume, “de novo” metastatic disease or metastatic recurrence of a disease initially localized at diagnosis) and raises the question of the potential benefit of earlier introduction of antiandrogens to improve disease outcomes. Due to the lack of trials comparing the AR inhibitors between each other, one would probably have to choose the antiandrogen according to the co-morbidity and general state and probably to the cost.

However, it remains difficult to precisely define the optimal time to begin these new antiandrogens, especially when these patients had already received docetaxel. Their usefulness in mCRPC, M0CRPC and m1CSPC is currently demonstrated. Indeed, the lack of survival results in patients who have previously received apalutamide and the fact that only 38% of patients in the apalutamide group received subsequent post-progression treatment may raise doubts about the appropriate time to start apalutamide in the disease evolution. One may wonder if the disease response to subsequent post-progression treatments could be optimized by taking previous apalutamide. Ongoing clinical trials are attempting to assess whether the introduction of these new antiandrogens before the emergence of metastases can delay the progression of the disease, particularly at the stage of low-risk localized diseases. This raises the issue of tolerance as well as the determination of criteria for selecting patients who could benefit from it.

**Acknowledgments**

None.

**Footnote**

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**References**